Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY, Robbins Y, Sievers C, Friedman J, Abdul Sater H, Clavijo PE, Judd N, Tsong E, Silvin C, Soon-Shiong P, Padget MR, Schlom J, Hodge J, Hinrichs C, Allen C. Lee MY, et al. Among authors: padget mr. J Immunother Cancer. 2021 Mar;9(3):e002128. doi: 10.1136/jitc-2020-002128. J Immunother Cancer. 2021. PMID: 33741731 Free PMC article.
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.
Jochems C, Hodge JW, Fantini M, Fujii R, Morillon YM 2nd, Greiner JW, Padget MR, Tritsch SR, Tsang KY, Campbell KS, Klingemann H, Boissel L, Rabizadeh S, Soon-Shiong P, Schlom J. Jochems C, et al. Among authors: padget mr. Oncotarget. 2016 Dec 27;7(52):86359-86373. doi: 10.18632/oncotarget.13411. Oncotarget. 2016. PMID: 27861156 Free PMC article.
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.
Giles AJ, Hao S, Padget M, Song H, Zhang W, Lynes J, Sanchez V, Liu Y, Jung J, Cao X, Fujii R, Jensen R, Gillespie D, Schlom J, Gilbert MR, Nduom EK, Yang C, Lee JH, Soon-Shiong P, Hodge JW, Park DM. Giles AJ, et al. Among authors: padget m. JCI Insight. 2019 Oct 17;4(20):e130688. doi: 10.1172/jci.insight.130688. JCI Insight. 2019. PMID: 31536478 Free PMC article.
Overcoming hypoxia-induced functional suppression of NK cells.
Solocinski K, Padget MR, Fabian KP, Wolfson B, Cecchi F, Hembrough T, Benz SC, Rabizadeh S, Soon-Shiong P, Schlom J, Hodge JW. Solocinski K, et al. Among authors: padget mr. J Immunother Cancer. 2020 Apr;8(1):e000246. doi: 10.1136/jitc-2019-000246. J Immunother Cancer. 2020. PMID: 32345623 Free PMC article.
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri MH, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM. Lampert EJ, et al. Among authors: padget m. Clin Cancer Res. 2020 Aug 15;26(16):4268-4279. doi: 10.1158/1078-0432.CCR-20-0056. Epub 2020 May 12. Clin Cancer Res. 2020. PMID: 32398324 Free PMC article. Clinical Trial.
21 results